Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvem…
Drug Manufacturers - Specialty & Generic
US, Newport Beach [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Evolus, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | -1.9200 | -3.089 | 0 | 33 | -46 | -97 | -46 | -99 | -35 | -114 | 29 | 52 |
| 2020 | -3.1900 | -1.741 | 34 | 57 | -90 | -99 | -92 | -36 | -94 | -37 | 113 | 90 |
| 2021 | -4.8300 | -0.974 | 56 | 99 | -163 | -55 | -144 | -63 | -68 | -66 | 98 | 157 |
| 2022 | -0.9400 | -0.920 | 99 | 148 | -46 | -90 | -39 | -76 | -63 | -83 | 112 | 234 |
| 2023 | -1.3300 | -0.556 | 148 | 201 | -74 | -61 | -60 | -90 | -57 | -98 | 141 | 194 |
| 2024 | -1.0800 | -0.215 | 202 | 264 | -61 | -12 | -41 | -158 | -49 | -165 | 164 | 416 |
| 2025 | - | -0.060 | - | 346 | - | -3 | - | -208 | - | -216 | - | 545 |
| 2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |